CLINICAL PROFILE OF CHEMOTHERAPY AMONG CANCER PATIENTS IN A TERTIARY CARE HOSPITAL- AN OBSERVATIONAL STUDY

Dr. Syeda Zaineb Kubra Hussaini*, Dr. Ram Prahlad K M, Riya Regi, Soha Sanobar, R. Sravani and
Ajay Babu

ABSTRACT

Background: Chemotherapy could certainly cure cancer, justifying including it into multimodality regimens with surgery and radiation treatment in the early stages of illness to give a therapeutic benefit. Since its inception, the primary barriers to chemotherapy's therapeutic success have been toxicity to normal tissues, tumour heterogeneity, and the development of cellular drug resistance.[1] Objective: To study the prognosis of chemotherapy, observe the diagnostic criteria of various types of cancer, and analyse various types of chemotherapy used in all types of cancer. Methods: A Hospital-based observational study of chemotherapy was conducted in tertiary care hospital for 6 months duration, with a sample size of 50 patients in the oncology inpatient and day care department of a tertiary care hospital. To begin, only medications that are somewhat successful against the same tumour when taken alone should be chosen for usage in combination. If they are available, medicines that cause some degree of full remission are recommended over those that cause just partial responses. When numerous medications of the same class are available and similarly effective, medication should be chosen based on its toxicity, which should not overlap with the toxicity of other medications to be used in combination. Results and Discussion: In this Prospective observational study, females (58%) were found to be more likely to suffer from cancer than male patients. Our study also revealed that 36-45 age group patients (30%)were found to be likely affected more in a population (n=50). Based on body weight difference between pre and post-chemotherapy,40-60 age group patients were found to have more weight difference (30%). the number of patients diagnosed with carcinoma was high (76%). Pre-medications of chemotherapy found that Dexamethasone (68%) and Ondansetron (68%) were mostly prescribed along with Ranitidine (30%). Conclusion: The study shows that a combination of Adriamycin and cyclophosphamide were the most commonly prescribed chemotherapeutic agents used for breast carcinoma for 22% of breast cancer patients and also the combination of cisplatin and paclitaxel which is a mitotic inhibitor were most commonly prescribed chemotherapeutic agents used for 16% of lung cancer.

Keywords: Chemotherapy, Carcinoma, Sarcoma.